Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
8.91
+0.30 (3.48%)
Nov 11, 2025, 4:00 PM EST - Market closed
Mersana Therapeutics Revenue
Mersana Therapeutics had revenue of $3.06M in the quarter ending June 30, 2025, with 33.28% growth. This brings the company's revenue in the last twelve months to $34.77M, up 16.14% year-over-year. In the year 2024, Mersana Therapeutics had annual revenue of $40.50M with 9.88% growth.
Revenue (ttm)
$34.77M
Revenue Growth
+16.14%
P/S Ratio
1.27
Revenue / Employee
$340,873
Employees
102
Market Cap
44.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 40.50M | 3.64M | 9.88% |
| Dec 31, 2023 | 36.86M | 10.27M | 38.65% |
| Dec 31, 2022 | 26.58M | 26.54M | 61,716.28% |
| Dec 31, 2021 | 43.00K | -785.00K | -94.81% |
| Dec 31, 2020 | 828.00K | -41.30M | -98.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MRSN News
- 2 days ago - Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 - GlobeNewsWire
- 3 months ago - Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewsWire
- 3 months ago - Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 5 months ago - Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - GlobeNewsWire
- 6 months ago - Mersana Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript - Seeking Alpha